1350: CA Repeat Polymorphism in the Insulin-Like Growth Factor-I (IGF-1) is Common Risk Factor of the Metabolic Syndrome and the Benign Prostatic Hyperplasia

2007 ◽  
Vol 177 (4S) ◽  
pp. 445-445
Author(s):  
Eunsik Lee ◽  
Woongeol Yeo ◽  
Kwan Jin Park ◽  
Seong Jin Jung ◽  
Seok-Soo Byun
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Repeat Polymorphism ◽  
Common Risk Factor ◽  
Ca Repeat ◽  
Factor I ◽  
The Metabolic Syndrome ◽  
Ca Repeat Polymorphism

120 Metabolic syndrome is an independent risk factor for benign prostatic hyperplasia

2012 ◽  
Vol 11 (1) ◽  
pp. e120
Author(s):  
K.J. Lin ◽  
S.H. Chu ◽  
H.W. Chen ◽  
T.M. Wang ◽  
Y.J. Chiang ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Benign Prostatic Hyperplasia ◽  
Independent Risk Factor ◽  
Prostatic Hyperplasia

Patient with hypertension, metabolic disorder and benign prostatic hyperplasia in the primary care physician’s office – the role of doxazosin

2021 ◽  
Vol 14 (3) ◽  
pp. 269-273
Author(s):  
Anna Nowak ◽  
Joanna Jarosz-Popek ◽  
Marek Postuła
Keyword(s):  
Primary Care ◽  
Metabolic Syndrome ◽  
Clinical Trials ◽  
Risk Factor ◽  
Benign Prostatic Hyperplasia ◽  
Adrenergic Receptor ◽  
Cardiovascular Complications ◽  
Prostatic Hyperplasia ◽  
Pleiotropic Action

In recent years, the therapy for patients with metabolic syndrome, which is a risk factor for cardiovascular complications, has become a challenge. Doxazosin – a selective α-adrenergic receptor antagonist, has emerged as a promising research target in the context of metabolic syndrome. It is pleiotropic action contributes to the reduction of metabolic syndrome indices. The results of clinical trials allow the construction of a promising, highly effective, and above all safe therapy in this group of patients.

scholarly journals A longitudinal study over 40 years to study the metabolic syndrome as a risk factor for cardiovascular diseases

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Lars Lind ◽  
Johan Sundström ◽  
Johan Ärnlöv ◽  
Ulf Risérus ◽  
Erik Lampa
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Longitudinal Study ◽  
Clinical Intervention ◽  
The Elderly ◽  
Adult Men ◽  
The Metabolic Syndrome ◽  
The Impact ◽  
Over 40 Years

AbstractThe impact of most, but not all, cardiovascular risk factors decline by age. We investigated how the metabolic syndrome (MetS) was related to cardiovascular disease (CVD) during 40 years follow-up in the Uppsala Longitudinal Study of Adult Men (ULSAM, 2,123 men all aged 50 at baseline with reinvestigations at age 60, 70, 77 and 82). The strength of MetS as a risk factor of incident combined end-point of three outcomes (CVD) declined with ageing, as well as for myocardial infarction, ischemic stroke and heart failure when analysed separately. For CVD, the risk ratio declined from 2.77 (95% CI 1.90–4.05) at age 50 to 1.30 (95% CI 1.05–1.60) at age 82. In conclusion, the strength of MetS as a risk factor of incident CVD declined with age. Since MetS was significantly related to incident CVD also at old age, our findings suggest that the occurrence of MetS in the elderly should not be regarded as innocent. However, since our data were derived in an observational study, any impact of MetS in the elderly needs to be verified in a randomized clinical intervention trial.

Sign in / Sign up

Export Citation Format

Share Document